Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Kawasumi Laboratories Inc Announces Extraordinary Profit and Amends Consolidated Full-year Outlook for FY 2013


Wednesday, 1 May 2013 04:45am EDT 

Kawasumi Laboratories Inc announced that it will record a JPY 1,180 million extraordinary profit on the insurance payout, for the fiscal year ended March 2013. In addition, the Company has lowered its consolidated full-year outlook for revenue from JPY 28,300 million to JPY 27,820 million, operating profit from JPY 750 million to JPY 420 million and ordinary profit from JPY 1,000 million to JPY 800 million, but raised the outlook for net profit from JPY 800 million to JPY 810 million and earning per share from JPY 34.98 to JPY 35.42, for the fiscal year ended March 2013. The Company lowered the outlook due to the decreased sales and the increased cost, and raised the net profit outlook due to the record of extraordinary profit, among others. 

Company Quote

634.0
-9.0 -1.40%
2:00am EDT